Macrogen Inc (038290) - Total Liabilities

Latest as of September 2025: ₩173.25 Billion KRW ≈ $117.41 Million USD

Based on the latest financial reports, Macrogen Inc (038290) has total liabilities worth ₩173.25 Billion KRW (≈ $117.41 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Macrogen Inc - Total Liabilities Trend (2011–2024)

This chart illustrates how Macrogen Inc's total liabilities have evolved over time, based on quarterly financial data. See Macrogen Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Macrogen Inc Competitors by Total Liabilities

The table below lists competitors of Macrogen Inc ranked by their total liabilities.

Company Country Total Liabilities
PannErgy Nyrt.
F:PPL
Germany €15.22 Billion
Kaiser Reef Ltd
AU:KAU
Australia AU$58.57 Million
Naim Holdings Bhd
KLSE:5073
Malaysia RM316.96 Million
Hurriyet Gazetecilik ve Matbaacilik AS
IS:HURGZ
Turkey TL2.59 Billion
Afluente Transmissão de Energia Elétrica S.A
SA:AFLT3
Brazil R$112.60 Million
Finger Inc.
KQ:163730
Korea ₩19.89 Billion
Seer Inc
NASDAQ:SEER
USA $30.65 Million
Genexine Inc
KQ:095700
Korea ₩106.21 Billion

Liability Composition Analysis (2011–2024)

This chart breaks down Macrogen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 038290 market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.86 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.13 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.51 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Macrogen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Macrogen Inc (2011–2024)

The table below shows the annual total liabilities of Macrogen Inc from 2011 to 2024.

Year Total Liabilities Change
2024-12-31 ₩152.23 Billion
≈ $103.17 Million
+54.35%
2023-12-31 ₩98.63 Billion
≈ $66.84 Million
-2.16%
2022-12-31 ₩100.80 Billion
≈ $68.31 Million
+0.27%
2021-12-31 ₩100.53 Billion
≈ $68.13 Million
+12.15%
2020-12-31 ₩89.64 Billion
≈ $60.75 Million
-20.11%
2019-12-31 ₩112.20 Billion
≈ $76.04 Million
+82.48%
2018-12-31 ₩61.49 Billion
≈ $41.67 Million
-27.17%
2017-12-31 ₩84.43 Billion
≈ $57.22 Million
+9.69%
2016-12-31 ₩76.97 Billion
≈ $52.16 Million
+32.26%
2015-12-31 ₩58.20 Billion
≈ $39.44 Million
+18.66%
2014-12-31 ₩49.05 Billion
≈ $33.24 Million
+77.29%
2013-12-31 ₩27.66 Billion
≈ $18.75 Million
-9.02%
2012-12-31 ₩30.41 Billion
≈ $20.61 Million
+107.57%
2011-12-31 ₩14.65 Billion
≈ $9.93 Million
--

About Macrogen Inc

KQ:038290 Korea Biotechnology & Medical Research
Market Cap
$94.13 Million
₩138.90 Billion KRW
Market Cap Rank
#19496 Global
#988 in Korea
Share Price
₩13860.00
Change (1 day)
-0.43%
52-Week Range
₩11490.00 - ₩19520.00
All Time High
₩49726.89
About

Macrogen, Inc. provides genetic and genomic analysis research services in South Korea and internationally. It offers next generation sequencing (NGS) services, such as whole genome, exome, targeted, transcriptome, metagenome, epigenome, and single cell multi-omics sequencing, as well as whole genome resequencing; and standard, difficult template, and 16S/18S/26S rRNA and ITS region sequencing ser… Read more